iMetabolic Biopharma Corporation (iMBP) is an exciting early stage platform biopharma company that is developing First In Class therapeutics for the treatment of a number of diseases with high unmet medical need. Through the application of its proprietary iPlatform technology, iMBP has established itself as a Leader in TechBio, a nouveau field of drug discovery and development driven by technology innovation. Having already established a pipeline of four early stage therapeutic assets, with additional molecules already in design phase, iMBP is at the precipice in its next leg of evolution. Based in Tempe, AZ; iMBP is growing its operations to support the development of both its platform technology and therapeutic pipeline. iMBP is now strategically poised to become a disruptive force in the biopharma industry and is poised to move forward ground breaking science to help improve patient care.